Mineralys Therapeutics, Inc. Common Stock Income Statement
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
2023
2022
2021
2020
0M
-
0M
0M
85M
14M
70M
-85M
0M
-72M
0M
-72M
141.28%
85M
10M
-85M
0M
0M
0M
-
0M
0M
31M
5M
26M
-31M
0M
-30M
0M
-30M
53.54%
31M
2M
-31M
0M
-31M
0M
-
0M
0M
19M
2M
16M
-19M
0M
-19M
0M
-19M
466.49%
19M
0M
-19M
0M
-19M
0M
-
0M
0M
3M
1M
2M
-3M
0M
-3M
0M
-3M
466.49%
3M
0M
-3M
0M
-3M
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
4Q2023
3Q2023
2Q2023
1Q2023
4Q2022
3Q2022
2Q2022
1Q2022
4Q2021
0M
-
0M
0M
28M
4M
24M
-28M
0M
-24M
0M
-24M
168.81%
28M
3M
-28M
0M
0M
0M
-
0M
0M
26M
4M
22M
-26M
0M
-23M
0M
-23M
240.82%
26M
4M
-26M
0M
0M
0M
-
0M
0M
16M
4M
12M
-16M
0M
-12M
0M
-12M
87.39%
16M
4M
-16M
0M
-16M
0M
-
0M
0M
15M
3M
12M
-15M
0M
-13M
0M
-13M
66.57%
15M
2M
-15M
0M
0M
0M
-
0M
0M
10M
2M
8M
-10M
0M
-9M
0M
-9M
28.10%
10M
1M
-10M
0M
-10M
0M
-
0M
0M
7M
1M
6M
-7M
0M
-7M
0M
-7M
28.10%
7M
1M
-7M
0M
0M
0M
-
0M
0M
6M
1M
6M
-6M
0M
-6M
0M
-6M
28.10%
6M
0M
-6M
0M
-6M
0M
-
0M
0M
8M
1M
7M
-8M
0M
-8M
0M
-8M
28.10%
8M
0M
-8M
0M
0M
0M
-
0M
0M
7M
0M
7M
-7M
0M
-7M
0M
-7M
28.10%
7M
0M
-7M
0M
0M